
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 28 years ago
Participating Facultyover 28 years ago
Current Approaches to Osteoporosis Preventionover 28 years ago
Patient-Provider Decisions About Long-Term Therapyover 28 years ago
An Emerging Approach to Osteoporosis Preventionover 28 years ago
The Management of the Patient with Osteoporosis: A Modern Epidemicover 28 years ago
CME Quizover 28 years ago
Selected Abstractsover 28 years ago
Bibliography





